Applications of pseudolaric acid B in preparation of anti-pulmonary-fibrosis medicines

A hibiscus acetic acid and pulmonary fibrosis technology, which is applied in the application field of hibiscus acetic acid in the preparation of anti-pulmonary fibrosis drugs, and can solve the problems that hibiscus acetic acid has not yet been used

Inactive Publication Date: 2017-08-15
LOGISTICS UNIV OF CAPF
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the application of hibiscus acetic acid in the preparation of anti-pulmonary fibrosis drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of pseudolaric acid B in preparation of anti-pulmonary-fibrosis medicines
  • Applications of pseudolaric acid B in preparation of anti-pulmonary-fibrosis medicines
  • Applications of pseudolaric acid B in preparation of anti-pulmonary-fibrosis medicines

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0022] The following embodiments and methods can enable those skilled in the art to understand the present invention more fully, but do not limit the present invention in any way

[0023] The extraction method of hibiscus acetic acid is as follows:

[0024] Extract the crude product from Hibiscus bark by heating under reflux with an ethanol aqueous solution with a volume concentration of 95%, and then extract the crude product with ethyl acetate to obtain an ethyl acetate extraction layer. Then separated and purified by silica gel column. After thin-layer chromatography analysis, the elution ratio of the mobile phase was selected: Silica CC (Φ35cm, 2.5cm), petroleum ether: ethyl acetate = 6:1, and pure PLAB (90%) was isolated.

[0025] Pharmacological experiment data:

[0026] Research on the role of hibiscus acetic acid in the preparation of anti-pulmonary fibrosis drugs:

[0027] 1 Materials and methods

[0028] 1.1 Experimental animals and materials

[0029] 40 4-week-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses applications of pseudolaric acid B in preparation of anti-pulmonary-fibrosis medicines. The structure of the pseudolaric acid B is shown as a formula (I). Experiments prove that the pseudolaric acid B (PLAB) obviously relieves the degree of alveolar catarrh and pulmonary fibrosis of mice in a pulmonary fibrosis model built by utilizing bleomycin, and inhibits collagen secretion and deposition in fibrotic lung tissues, thus preventing and treating pulmonary fibrosis.

Description

technical field [0001] The invention relates to the application of hibiscus acetic acid in the preparation of anti-pulmonary fibrosis medicine. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) refers to the abnormal repair of alveolar epithelial cells after injury, resulting in the transformation of pulmonary fibroblasts into myofibroblasts, excessive secretion of extracellular matrix, collagen deposition, and changes in alveolar structure. , eventually forming fibrosis. Its pathogenesis has not been fully clarified, and current studies suggest that it is closely related to oxidative stress, inflammatory response, and humoral regulation of the renin-angiotensin-aldosterone system (RAAS) [1-3] . Excessive ROS produced by oxidative stress leads to necrosis of lung epithelial cells, induces inflammatory response and cytokine network disorder, promotes the increase of interleukin, transforming growth factor β1 (TGF-β1), connective tissue growth factor (CTGF), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P11/00
CPCA61K31/366
Inventor 曹波刘斌齐莉陈虹高晨光王火陈亚泽李俸敏
Owner LOGISTICS UNIV OF CAPF
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap